About Brenus Pharma
Brenus Pharma is a company based in Issoire (France) founded in 2020. Brenus Pharma has raised $25 million across 1 funding round from investors including Crédit Agricole, Angelor and UI Investissement. Brenus Pharma offers products and services including STC 1010 and STC Platform. Brenus Pharma operates in a competitive market with competitors including IGM Biosciences, Imvax, Check-Cap, BriaCell Therapeutics and New Element Medicine, among others.
- Headquarter Issoire, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25 M (USD)
in 1 rounds
-
Latest Funding Round
$25 M (USD), Series A
Sep 18, 2024
-
Investors
Crédit Agricole
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Brenus Pharma
Brenus Pharma offers a comprehensive portfolio of products and services, including STC 1010 and STC Platform.
Immunotherapy targeting colorectal cancer to educate immune system against relapse.
Allogeneic system generating tumor antigen-focused treatments for solid tumors.
People of Brenus Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Brenus Pharma
Brenus Pharma has successfully raised a total of $25M through 1 strategic funding round. The most recent funding activity was a Series A round of $25 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Brenus Pharma
Brenus Pharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Angelor and UI Investissement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UI Investissement is engaged in private equity and investment services.
|
Locked | Locked | Locked | |
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Locked | Locked | Locked | |
|
Investsud is engaged in supporting SMEs with sustainable investments.
|
Locked | Locked | Locked |
Investor details for Brenus Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Brenus Pharma
Investment portfolio details for Brenus Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Brenus Pharma
Detailed financials for Brenus Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Brenus Pharma Comparisons
Peer comparison for Brenus Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Brenus Pharma
Brenus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IGM Biosciences, Imvax, Check-Cap, BriaCell Therapeutics and New Element Medicine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibodies for cancer and infectious disease treatments are developed.
|
|
| Locked | Locked | Locked |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of imaging capsules for colorectal cancer screening
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of cancer
|
|
| Locked | Locked | Locked |
Drugs for cancer and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases are developed using Aminoacyl-tRNA Synthetase technology.
|
Detailed competitors of Brenus Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Brenus Pharma
Complete news archive for Brenus Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brenus Pharma
Brenus Pharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Brenus Pharma is headquartered in Issoire, France. It is registered at Issoire, Auvergne-rhone-alpes, France.
Jacques Gardette is the current CEO of Brenus Pharma.
Brenus Pharma is a funded company, having raised a total of $25M across 1 funding round to date.
Brenus Pharma was founded in 2020 in Issoire, France, where focus is placed on biotechnology for oncology. Immunotherapy solutions are developed, with STC-1010 targeted at metastatic colorectal cancer and other solid tumors. Operations center on advancing clinical-stage treatments within the pharmaceutical sector, supporting research and development for cancer therapies across Europe.
Brenus Pharma's top competitors include Imvax, IGM Biosciences and Check-Cap.
Brenus Pharma offers STC 1010 and STC Platform.
Brenus Pharma has 5 investors. Key investors include Crédit Agricole, Angelor, UI Investissement, Noshaq, and Investsud.